NASDAQ:AUTL Autolus Therapeutics (AUTL) Stock Forecast, Price & News $2.26 -0.07 (-3.00%) (As of 10:20 AM ET) Add Compare Share Share Today's Range$2.26▼$2.3550-Day Range$2.32▼$3.3652-Week Range$1.60▼$3.54Volume38,976 shsAverage Volume551,423 shsMarket Capitalization$392.52 millionP/E RatioN/ADividend YieldN/APrice Target$7.80 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Autolus Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside234.8% Upside$7.80 Price TargetShort InterestHealthy0.93% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.97) to ($0.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.28 out of 5 starsMedical Sector348th out of 968 stocksBiological Products, Except Diagnostic Industry54th out of 161 stocks 3.5 Analyst's Opinion Consensus RatingAutolus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.80, Autolus Therapeutics has a forecasted upside of 234.8% from its current price of $2.33.Amount of Analyst CoverageAutolus Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.93% of the outstanding shares of Autolus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAutolus Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Autolus Therapeutics has recently increased by 17.52%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAutolus Therapeutics does not currently pay a dividend.Dividend GrowthAutolus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUTL. Previous Next 2.5 News and Social Media Coverage News SentimentAutolus Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Autolus Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for AUTL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.78% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.97) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Autolus Therapeutics is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Autolus Therapeutics is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAutolus Therapeutics has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Autolus Therapeutics (NASDAQ:AUTL) StockAutolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.Read More AUTL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AUTL Stock News HeadlinesSeptember 11, 2023 | seekingalpha.comAutolus: CAR-T Therapy Looks PromisingSeptember 10, 2023 | seekingalpha.comAutolus Therapeutics: Innovating T Cell Cancer TreatmentsOctober 2, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. September 5, 2023 | finance.yahoo.comAutolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal BloodAugust 23, 2023 | fool.comAutolus Therapeutics Plc (NASDAQ: AUTL)August 7, 2023 | insidermonkey.comAutolus Therapeutics plc (NASDAQ:AUTL) Q2 2023 Earnings Call TranscriptAugust 4, 2023 | finance.yahoo.comAutolus Therapeutics (NASDAQ:AUTL) Is In A Good Position To Deliver On Growth PlansAugust 4, 2023 | seekingalpha.comAutolus Therapeutics plc 2023 Q2 - Results - Earnings Call PresentationOctober 2, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. August 3, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Autolus Therapeutics (AUTL), Intercept Pharma (ICPT)August 3, 2023 | msn.comAutolus Therapeutics GAAP EPS of -$0.26 misses by $0.03August 3, 2023 | finance.yahoo.comAutolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational ProgressJuly 28, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts FridayJuly 19, 2023 | markets.businessinsider.comAutolus Therapeutics Appoints Robert Dolski CFOJuly 18, 2023 | finance.yahoo.comAutolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023July 6, 2023 | finance.yahoo.comAutolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic LeukemiaJune 30, 2023 | seekingalpha.comAutolus Therapeutics Could Hold A Winning CAR T-Cell TicketJune 27, 2023 | finance.yahoo.comAutolus Therapeutics announces publication in Cancer Immunology ResearchJune 20, 2023 | finance.yahoo.comAutolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive DirectorJune 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Anixa Biosciences (ANIX)June 16, 2023 | finance.yahoo.comAutolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell LymphomaJune 6, 2023 | finance.yahoo.comAutolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023June 2, 2023 | markets.businessinsider.comNeedham Sticks to Their Buy Rating for Autolus Therapeutics (AUTL)June 2, 2023 | markets.businessinsider.comWhere Autolus Therapeutics Stands With AnalystsMay 12, 2023 | finance.yahoo.comAutolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHAMay 7, 2023 | seekingalpha.comAutolus Therapeutics plc 2023 Q1 - Results - Earnings Call PresentationMay 6, 2023 | msn.comWells Fargo Maintains Autolus Therapeutics plc - ADR (AUTL) Overweight RecommendationSee More Headlines Receive AUTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AUTL Company Calendar Last Earnings8/03/2023Today10/02/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AUTL CUSIPN/A CIK1730463 Webwww.autolus.com Phone442038296230FaxN/AEmployees399Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.80 High Stock Price Forecast$12.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+240.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-148,840,000.00 Net MarginsN/A Pretax Margin-2,321.52% Return on Equity-64.88% Return on Assets-37.26% Debt Debt-to-Equity RatioN/A Current Ratio8.65 Quick Ratio8.65 Sales & Book Value Annual Sales$6.36 million Price / Sales62.54 Cash FlowN/A Price / Cash FlowN/A Book Value$1.73 per share Price / Book1.32Miscellaneous Outstanding Shares173,680,000Free Float129,045,000Market Cap$397.73 million OptionableNot Optionable Beta1.54 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Christian Martin Itin Ph.D. (Age 59)CEO & Director Comp: $2.68MDr. Martin Pule M.D. (Age 51)MBBS, Founder, Sr. VP & Chief Scientific Officer Mr. Christopher Vann (Age 58)Sr. VP & COO Mr. David Brochu (Age 67)Sr. VP & Chief Technical Officer Mr. Brent Rice (Age 57)Sr. VP, Chief Commercial Officer & Site Head of US Dr. Edgar E. W. Braendle M.D. (Age 63)Ph.D., Sr. VP & Chief Devel. Officer Mr. Robert F. Dolski (Age 53)Chief Financial Officer Ms. Olivia ManserDirector of Investor RelationsDr. Chris Williams (Age 43)Sr. VP of Corp. Devel. Mr. Alexander SwanChief HR OfficerMore ExecutivesKey CompetitorsiTeos TherapeuticsNASDAQ:ITOSIcosavaxNASDAQ:ICVXCullinan OncologyNASDAQ:CGEMScholar RockNASDAQ:SRRKCaribou BiosciencesNASDAQ:CRBUView All CompetitorsInstitutional OwnershipAffinity Asset Advisors LLCBought 1,589,017 shares on 8/21/2023Ownership: 0.915%Wells Fargo & Company MNBought 32,073 shares on 8/15/2023Ownership: 0.299%Goldman Sachs Group Inc.Bought 71,378 shares on 8/15/2023Ownership: 0.054%Citadel Advisors LLCSold 300 shares on 8/15/2023Ownership: 0.000%Tower Research Capital LLC TRC Sold 4,352 shares on 8/14/2023Ownership: 0.015%View All Institutional Transactions AUTL Stock - Frequently Asked Questions Should I buy or sell Autolus Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AUTL shares. View AUTL analyst ratings or view top-rated stocks. What is Autolus Therapeutics' stock price forecast for 2023? 5 brokers have issued twelve-month target prices for Autolus Therapeutics' shares. Their AUTL share price forecasts range from $5.00 to $12.00. On average, they expect the company's stock price to reach $7.80 in the next twelve months. This suggests a possible upside of 240.6% from the stock's current price. View analysts price targets for AUTL or view top-rated stocks among Wall Street analysts. How have AUTL shares performed in 2023? Autolus Therapeutics' stock was trading at $1.90 at the beginning of the year. Since then, AUTL shares have increased by 20.5% and is now trading at $2.29. View the best growth stocks for 2023 here. Are investors shorting Autolus Therapeutics? Autolus Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 1,610,000 shares, an increase of 17.5% from the August 31st total of 1,370,000 shares. Based on an average daily volume of 441,500 shares, the short-interest ratio is presently 3.6 days. View Autolus Therapeutics' Short Interest. When is Autolus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our AUTL earnings forecast. How were Autolus Therapeutics' earnings last quarter? Autolus Therapeutics plc (NASDAQ:AUTL) posted its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.04. What ETF holds Autolus Therapeutics' stock ? Range Cancer Therapeutics ETF holds 44,025 shares of AUTL stock, representing 1.33% of its portfolio. What other stocks do shareholders of Autolus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Autolus Therapeutics investors own include Sorrento Therapeutics (SRNE), CRISPR Therapeutics (CRSP), VBI Vaccines (VBIV), GW Pharmaceuticals (GWPH), ImmunoGen (IMGN), Teva Pharmaceutical Industries (TEVA), TG Therapeutics (TGTX), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP) and Advanced Micro Devices (AMD). When did Autolus Therapeutics IPO? (AUTL) raised $125 million in an initial public offering on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers. What is Autolus Therapeutics' stock symbol? Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL." How do I buy shares of Autolus Therapeutics? Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Autolus Therapeutics' stock price today? One share of AUTL stock can currently be purchased for approximately $2.29. How much money does Autolus Therapeutics make? Autolus Therapeutics (NASDAQ:AUTL) has a market capitalization of $397.73 million and generates $6.36 million in revenue each year. The company earns $-148,840,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. How many employees does Autolus Therapeutics have? The company employs 399 workers across the globe. How can I contact Autolus Therapeutics? Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The official website for the company is www.autolus.com. The company can be reached via phone at 442038296230 or via email at ir@autolus.com. This page (NASDAQ:AUTL) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.